Изосорбида мононитрат

Quick links

Choose a section

Quick links to important sections

Advertisements

Изосорбида мононитрат

Advertisements
Advertisements
Advertisements

Overview of Изосорбида мононитрат

Quick Facts

Property Description
Active ingredient Isosorbide Mononitrate
Form Tablets (immediate- and extended-release)
Pharmacological class Organic Nitrates, Vasodilators
General purpose Prophylaxis of Angina Pectoris
Origin Synthetic

Что такое Изосорбида мононитрат и к какому классу относится?

Изосорбида мононитрат (Isosorbide Mononitrate) is a synthetic chemical compound classified as an organic nitrate, functioning as a powerful vasodilator. The active substance, Isosorbide-5-mononitrate, is a stable glucitol derivative that is inherently active in the body, meaning it readily exerts its effect without requiring the extensive prior metabolic conversion necessary for some related medicines. This intrinsic activity is clinically recognized for providing high and consistent oral bioavailability, making it well-suited for reliable long-term therapeutic use. The agent is available only by prescription and is recognized as a key antianginal agent within its therapeutic class.


Принцип действия и основное назначение

The core principle of action for Isosorbide Mononitrate is the promotion of widespread vasodilation, which occurs when the medicine releases Nitric Oxide into the circulatory system. This mechanism causes the smooth muscles in the walls of blood vessels to relax, primarily affecting the large veins. By causing a significant reduction in the volume of blood returning to the heart—a process termed decreased cardiac preload—the medication effectively lessens the overall workload on the heart muscle. The established clinical purpose of the drug is the prophylaxis (prevention) of chronic episodes of heart-related chest discomfort, or angina pectoris, ensuring a continuous balance between the heart's oxygen supply and demand, a scenario frequently seen in patients with coronary artery disease.


Основные фармацевтические формы

The drug is designed for oral administration and is supplied as tablets, formulated to contain a single active ingredient. Key pharmaceutical forms include both immediate-release and extended-release tablets. The extended-release system, which offers sustained action, is particularly noted for its design, aiming to provide consistent, stable therapeutic levels over a prolonged period. This feature is essential for supporting patient adherence and effective long-term management of chronic cardiovascular conditions.

Advertisements

What side effects are possible with Изосорбида мононитрат?

Possible side effects and safety information

The official safety profile for Isosorbide Mononitrate is primarily characterized by adverse reactions stemming from its vasodilating action, as classified in government regulatory documents.


Frequency-Classified Adverse Reactions

Adverse reactions are classified by frequency based on data found in regulatory labeling:

  • Very Common (ge 1/10): Headache.
  • Common (ge 1/100 to < 1/10): Dizziness, Nausea, Vomiting, Hypotension (low blood pressure), Tachycardia (increased heart rate).
  • Uncommon (ge 1/1,000 to < 1/100): Transient flushing, Hypersensitivity reactions (e.g., skin rash, pruritus).

Headache is often observed at the initiation of therapy and is described in official documents as typically diminishing with continued use.


System-Organ Classes and Serious Reactions

Adverse effects are documented across several systems, including the Nervous System (headache, dizziness, syncope), Vascular Disorders (hypotension, flushing), and Gastrointestinal Disorders (nausea, vomiting).

Serious adverse reactions documented in regulatory sources include severe hypotension and syncope (fainting), which are rare but clinically significant.


Safety-Related Restrictions

The most critical regulatory constraint involves an absolute prohibition on the concomitant use of Isosorbide Mononitrate with Phosphodiesterase Type 5 (PDE5) inhibitors (such as sildenafil or tadalafil). This restriction is explicitly stated due to the risk of profound, life-threatening hypotension and circulatory collapse.

Furthermore, regulatory information advises caution and monitoring for individuals with severe hepatic or renal impairment and notes that the hypotensive effect may be exaggerated in patients with pre-existing low blood pressure or severe anemia.

Advertisements

Overdose and Emergency Response

The official regulatory profile for Isosorbide Mononitrate overdose indicates that the primary clinical manifestation is severe hypotension, resulting from excessive vasodilation. Documented overdose presentations include a prompt fall in blood pressure, syncope, persistent throbbing headache, confusion, visual disturbances, vertigo, and sometimes nausea or vomiting. These signs may escalate to reduced cardiac output and, potentially, circulatory failure.

Life-Threatening Manifestations

A rare but life-threatening complication documented in labeling is Methemoglobinemia, characterized by cyanosis, which requires specific intervention. Urgent medical attention must be sought immediately for symptoms such as syncope, severe persistent headache with confusion, or any sign of cyanosis, as these indicate a serious, life-threatening scenario.

Management and Monitoring

The required emergency management is directed toward increasing the central fluid volume, often through intravenous infusion or passive elevation of the patient's legs. The use of Methylene Blue is the stated treatment for Methemoglobinemia. Patients are required to undergo observation for at least 12 hours to monitor blood pressure and pulse. Regulatory documents advise caution with fluid expansion measures in patients with pre-existing renal disease or congestive heart failure.

Advertisements

Therapeutic Uses of Изосорбида мононитрат

Isosorbide mononitrate is a long-acting medication primarily used to manage and help reduce the likelihood of episodes of angina pectoris (chest pain) in individuals with coronary artery disease. It is generally prescribed as a maintenance therapy, with the goal of alleviating the chest discomfort, pressure, or pain associated with insufficient blood supply to the heart muscle. The long-term use of this medication may support the patient’s ability to participate in regular daily activities by helping to lessen the frequency of these painful symptoms. The main indication for its use is the prevention and long-term management of chronic stable angina. The medication is part of the nitrate class of drugs, which may assist in controlling symptoms associated with this condition. The overall patient benefit is an expected reduction in the occurrence of angina attacks.


Quick Fact: Relief for Chest Pain

Regulatory References

  1. NIH MedlinePlus guidance
Advertisements

Eligibility and Restrictions for Use

Official Eligibility Profile

The regulatory documentation for Isosorbide Mononitrate establishes clear eligibility rules centered on patient status and concurrent pharmacological use.

Eligibility Scope Status
Primary Population Adults with chronic stable angina pectoris.
Pediatric Patients Use not established; safety and effectiveness have not been determined.
Pregnant/Lactating Safety not established; use is conditional on potential benefit outweighing potential risk.

Absolute Contraindications: The medicine is strictly contraindicated in patients with a known hypersensitivity to nitrates or any excipients. Use is also prohibited in patients taking Phosphodiesterase Type 5 (PDE-5) Inhibitors (e.g., Sildenafil) or Soluble Guanylate Cyclase (sGC) Stimulators (e.g., Riociguat). Furthermore, Isosorbide Mononitrate must not be used in acute cardiovascular emergencies, including Cardiogenic Shock, circulatory collapse, or cases of Marked Hypotension.

Conditional Use and Comorbidities: Use requires caution in older adults due to susceptibility to low blood pressure, and in patients with conditions like Hypertrophic Cardiomyopathy or severe anemia. Regulatory data indicates that dose adjustments are not generally required for patients with pre-existing hepatic (liver) or renal (kidney) impairment, as clearance remains similar to that of healthy subjects.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents detail specific drug–drug and drug–substance interactions that affect the use of Isosorbide Mononitrate. The interaction profile is primarily defined by the potential for additive vasodilatory effects.


Formal Regulatory Restrictions

Co-administration with specific medications is contraindicated due to the high risk of severe hypotension and cardiovascular collapse. This restriction applies to the class of Phosphodiesterase type 5 (PDE5) Inhibitors, including Sildenafil, Tadalafil, and Vardenafil, as well as the Soluble Guanylate Cyclase (sGC) Stimulator, Riociguat. These combinations are explicitly prohibited.

Pharmacodynamic and Substance Interactions

Isosorbide Mononitrate exhibits additive pharmacodynamic effects when used with other agents that lower blood pressure. Concomitant use with other vasodilators and certain antihypertensive agents, such as Calcium Channel Blockers, may cause exaggerated hypotensive effects, including symptomatic orthostatic hypotension. The consumption of alcohol (ethanol) is also documented to have additive vasodilating effects, potentially increasing the risk of light-headedness or hypotension.

Exposure Modification

When co-administered with Dihydroergotamine, Isosorbide Mononitrate may increase the blood plasma levels of Dihydroergotamine, thereby potentially intensifying its hypertensive effect. Regulatory data also note that for the extended-release tablets, taking the medicine with food may decrease the rate of absorption, though the total amount absorbed remains unchanged.

Advertisements

Mechanism of Action

Molecular Activation of the NO-cGMP Pathway

The core mechanism involves the molecule acting as a precursor that releases Nitric Oxide (NO) within the smooth muscle cells lining the blood vessels. This NO directly activates the enzyme soluble Guanylate Cyclase (sGC), which increases the intracellular levels of the signaling molecule cyclic Guanosine Monophosphate (cGMP), initiating the resulting cellular sequence that leads to smooth muscle relaxation.


Venous Dilation and Preload Reduction

The resultant vasodilation (vessel widening) predominantly affects the veins, causing blood to pool peripherally and thereby decreasing the volume of blood returning to the heart. This reduction in preload directly translates into a lowered volume and pressure inside the ventricles, which subsequently decreases the heart’s workload and oxygen demand.


Mechanistic Limitations: The Role of Tolerance

The drug's mechanism is subject to a phenomenon known as tolerance, or tachyphylaxis, where continuous, uninterrupted exposure can lead to a temporary attenuation of the physiological effect. This is biologically attributed to the potential depletion of necessary sulfhydryl groups (thiols) required for the sustained release of NO. This requires a period of low plasma concentration to allow for the restoration of full pathway activity.

Advertisements

Dosage and Administration Information

How to Use Изосорбида мононитрат

Isosorbide Mononitrate is administered exclusively through the oral route and is available in both immediate-release (IR) and extended-release (ER) tablets. The administration schedule is precisely defined to maintain long-term effectiveness.

For the IR form, the dosing is typically twice daily, with doses scheduled asymmetrically (e.g., separated by seven hours) to ensure a necessary drug-free interval is established each day. The typical maintenance range for IR tablets is 20 mg to 40 mg twice daily. The extended-release tablets are taken once daily in the morning. This once-a-day schedule is specifically designed to provide a sustained therapeutic level during the day while allowing the required period of low drug concentration to occur overnight. The initial dose for the extended-release form is usually 30 mg or 60 mg, which may be gradually titrated upward to a maximum maintenance dose of 120 mg once daily.


The medicine can be taken with or without food, as its absorption is not significantly affected by meals. A key administration constraint applies to the extended-release form: the tablets must be swallowed whole and must not be crushed or chewed to preserve the sustained-action mechanism. For older adults, the initial dose may be started at the low end of the range, with dose adjustment conducted with caution. If a dose is missed, the instruction is to take the next scheduled dose at the usual time and not taking two doses together to catch up. This procedural structure ensures the stable, time-dependent use necessary for chronic maintenance.

Advertisements

Recent Clinical Evidence

Research on Use in Chronic Stable Angina Pectoris

Isosorbide mononitrate was studied in research settings focusing on prevention for individuals with chronic stable angina pectoris—a condition characterized by fluctuating or episodic manifestations of chest discomfort. The primary research consists of Randomized Controlled Trials (RCTs), which explored the medicine compared to placebo (an inactive substance). These RCTs were also applied to research examining extended-release formulations, which were evaluated in research contexts used in studies exploring how symptoms change over time.

Studies monitored outcomes related to physical discomfort, such as the frequency of angina attacks and the consumption of short-acting relief medication. Research also evaluated outcomes reflecting daily functioning or activity level, measured using standardized exercise tests. Patterns were observed that data show patterns related to changes measured during the study period in relation to episodic manifestations of angina. Studies report how symptoms evolved in the observed populations. Research provides insight into short-term changes related to changes in the frequency of angina episodes.


Long-Term Research and Observation Periods

Follow-up durations were limited in the research. While some RCTs explored changes over several weeks to assess early responses, other studies continued monitoring for several months. These studies were applied to research exploring the durability of the observed patterns over defined time intervals.

Long-term effects are not fully established in terms of continuation of observed patterns of outcomes related to physical discomfort during continuous use. Evidence is limited regarding how the medicine may sustain the observed patterns over significantly longer periods.


Research in Specific Patient Groups

Isosorbide mononitrate was evaluated in populations consisting mainly of adult patients with chronic stable angina pectoris. Research examined patient subgroups stratified by disease severity, using scales defined within the study context.

Evidence is limited for certain other specific groups. Data for certain groups remain insufficient, and results apply only to the populations studied. Subgroup findings are uncertain in the context of a wide patient sample.


Unproven Questions and Research Gaps

Research describes what has been observed so far concerning symptomatic control. However, research limitation frames apply to the overall evidence base. Studies do not monitor the impact of Isosorbide mononitrate on major cardiovascular events, such as preventing myocardial infarction or mortality; long-term effects are not fully established in this area.

Pharmacological tolerance (a potential shift in observed changes during constant use) was associated with long-term nitrate use. This characteristic was observed in some studies that examined temporary physiological imbalance; this phenomenon remains a key limitation. Findings indicate that mixed patterns were observed for some patients during the study period. Evidence highlights what is known — and what is still uncertain.

Key Studies & References

  1. [Efficacy and length of action of a slow-release formulation of isosorbide-5-mononitrate in stable effort angina]
  2. Isosorbide Mononitrate Extended-Release Tablets, USP: FDA Label (DailyMed)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Изосорбида мононитрат (FAQ)


Q: What is the standard storage temperature for the medication?

According to official product information, this medicine should be stored at a controlled room temperature, which is between 15 C and 30 C (59 F and 86 F). The product information states that the container should be kept tightly closed and protected from excessive moisture and heat to maintain its stability.


Q: How does this medicine help my heart and chest pain?

The medicine is indicated for preventing episodes of chronic chest pain (angina pectoris) that are related to coronary artery disease. It functions by relaxing and widening the blood vessels. This effect reduces the volume of blood returning to the heart, which in turn lessens the heart's workload and its demand for oxygen.


Q: What should I do if I accidentally miss a dose?

Regarding a missed dose, the official instructions advise that the next scheduled dose should be taken at the usual time. Regulatory instructions also state that two doses should not be taken together to make up for a previously missed dose.


Q: Can I take this if I have a heart condition other than angina?

Official information states that the medicine is strictly prohibited in acute cardiovascular emergencies, such as cardiogenic shock or circulatory collapse. Caution is advised for use in patients with certain other conditions, including severe anemia or hypertrophic cardiomyopathy. Regulatory documents emphasize the need for healthcare providers to be aware of all existing heart conditions before treatment initiation.


Q: How long does it take for the pill to start working?

For the immediate-release tablet, official data indicates that the antianginal effect is present around one hour after the dose, with the peak effect typically occurring between one and four hours. The extended-release form is designed to provide sustained antianginal activity for at least 12 hours after a once-daily morning dose.


Q: Is there a pediatric dose of Isosorbide Mononitrate?

Safety and effectiveness have not been established for the use of this medicine in pediatric patients, according to regulatory guidelines. Due to this, there is no official dosage guidance established for children.


Q: What should I do if my headache doesn't go away after the first week of treatment?

Headache is a very common, expected side effect, especially when treatment begins, and it is usually noted to diminish with continued use. Regulatory guidance indicates that if headaches persist or become severe, a healthcare professional should be consulted. In some cases, simple pain relievers may be used for headache relief, though it is best to discuss this with a healthcare professional.

Advertisements

How should Изосорбида мононитрат be stored and disposed of?

Official Storage and Disposal Instructions

Isosorbide mononitrate tablets must be stored at controlled room temperature, specifically between 15 C and 30 C (59 F and 86 F), to maintain product stability.

Storage Condition Requirement Child Safety/Disposal
Temperature Store between 15 C–30 C. Do not freeze or expose to excess heat. Keep out of the reach of children
Protection Protect from excessive moisture and keep away from direct light. Dispose of expired/unused product according to local regulations
Container Keep the container tightly closed in the original packaging. Do not flush or dispose of into sewer systems

Official labeling mandates that the product be kept in a tight, closed container and protected from environmental factors like moisture and heat. Disposal of any unused or expired tablets must comply with local and national pharmaceutical waste regulations, and the medicine should be kept secured and out of children's reach at all times.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Изосорбида мононитрат found in:

A-Z Index: